Legal Battles and Medical Innovations: A Week in Health News
The health news this week highlights key legal and medical developments. Danco Laboratories is challenging a court's decision that blocks mail-order access to abortion drug mifepristone. Canada approves a generic version of the diabetes drug Ozempic. The FDA approves a new breast cancer drug by Pfizer and Arvinas.
Danco Laboratories has filed an application with the U.S. Supreme Court to halt a decision that restricts mail-order access to the abortion drug mifepristone. The move follows a ruling by a conservative panel, affecting widespread availability, particularly in states banning abortion.
On a different note, Canada's health regulator has approved a generic version of the diabetes medication Ozempic, developed by Apotex, marking it as the second generic alternative authorized in the country.
In other pharmaceutical developments, the U.S. FDA has approved a breast cancer drug from Pfizer and Arvinas, offering new treatment options for advanced estrogen receptor-positive, HER2-negative breast cancer.
(With inputs from agencies.)
Advertisement
ALSO READ
Soccer-Canada will spend C$1 billion to host World Cup, watchdog says
UPDATE 1-Israel's treatment of Gaza flotilla members is 'abominable', Canada PM Carney says
Canada to protest to Israel about treatment of Gaza flotilla members
Canada dismisses Russia's claim that Baltic nations are allowing drone strikes
Agnico Eagle to redevelop Hope Bay gold mine in Canada's Arctic, government says
Google News